1. Academic Validation
  2. The E3 ligases Itch and WWP2 regulate autoimmune neuroinflammation by controlling TH2 to TH17 cell conversion via interleukin-4-STAT5 axis in mice

The E3 ligases Itch and WWP2 regulate autoimmune neuroinflammation by controlling TH2 to TH17 cell conversion via interleukin-4-STAT5 axis in mice

  • Nat Commun. 2026 Jan 23;17(1):952. doi: 10.1038/s41467-025-67665-w.
Mei Zhao 1 Chao Zhang 2 Xin Zhang 2 3 Qingdian Mu 2 Qian Li 2 Yun-Cai Liu 4 5
Affiliations

Affiliations

  • 1 Institute for Immunology and School of Basic Medical Science, Tsinghua University, Beijing, China. [email protected].
  • 2 Institute for Immunology and School of Basic Medical Science, Tsinghua University, Beijing, China.
  • 3 Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China.
  • 4 Institute for Immunology and School of Basic Medical Science, Tsinghua University, Beijing, China. [email protected].
  • 5 Tsinghua-Peking Center for Life Sciences, Tsinghua University, Beijing, China. [email protected].
Abstract

Multiple sclerosis (MS) is a neurodegenerative autoimmune disease primarily mediated by T helper 17 (TH17) cells. We previously showed that Itch/WWP2 double knockout (DKO) T cells produce high levels of type 2 cytokines, driving spontaneous autoinflammation. Here, we report that DKO TH2-high carrying autoantigen-specific TCR (2D2) develop atypical spontaneous experimental autoimmune encephalomyelitis (EAE), with CD4+ T cells simultaneously producing IL-4 and GM-CSF, directly causing neuroinflammation. Unexpectedly, IL-4 deletion in DKO TH2-high 2D2 mice exacerbates TH17-driven classical EAE, indicating a TH2 to TH17 conversion. Furthermore, we show that the JAK3/STAT5 signaling pathway is critical for maintaining TH2 lineage stability by modulating Blimp1 and c-Maf thereby suppressing TH17 differentiation. Importantly, we find that this phenomenon can also be observed in dupilumab-treated patients with atopic dermatitis who develop psoriasis. Thus, our findings uncover the molecular antagonism and plasticity in the TH2 and TH17 cell programs and identify potential therapeutic targets for modulating TH2 and TH17 cell responses in autoimmune diseases.

Figures
Products